Louisiana Attorney General Challenges FDA Over Abortion Pill Distribution

Louisiana Attorney General Liz Murrill squared off against the FDA and major pharmaceutical companies in a New Orleans courtroom this week, arguing that abortion-inducing drugs should not be shipped into the state. According to WBRZ reporting from the hearing, Murrill is pushing to limit these medications to in-person prescription and dispensation — a move reproductive rights advocates warn could ripple far beyond Louisiana's borders.

A single lawsuit with fifty-state implications

Murrill told the court that pharmaceutical companies are profiting from what she called the illegal distribution of these drugs in Louisiana. "They make a lot of money off of the illegal distribution of drugs in our state, and they should be joining with us to prevent the illegal distribution of these drugs in our state, especially when we have evidence of women being poisoned by these drugs," she said.

For opponents of the suit, the danger is geographic rather than local. Hudson, senior counsel at the Center for Reproductive Rights, argued that a win for Louisiana could constrain access everywhere else. "Even in states where the people have voted to enshrine protections of abortion in their constitution, they would not be able to access abortions via mail," Hudson said. The same attorney tied the case directly to the post-Dobbs landscape: "Keep in mind that this is all coming on the heels of the Dobbs decision, in which the Supreme Court said that each state can decide, but Louisiana, a single state, is trying to impose its opinion on all other 49 states, plus territories."

The litigation grew out of a West Baton Rouge case in which a mother allegedly forced her teenage daughter to take abortion-inducing drugs; District Attorney Tony Clayton's office prosecuted the mother and a New York doctor for providing an abortion with drugs obtained through the mail. Murrill has said she expects the dispute to reach the Supreme Court, though no timeline has been set.

What this changes for patients — and what to watch

In 2024, Governor Jeff Landry signed a law reclassifying abortion drugs as controlled substances, making possession without a prescription a crime in Louisiana. The new lawsuit is the legal pressure valve on top of that statute. For anyone in the state weighing their options, the practical math has shifted: medication obtained by mail, even from a telehealth provider operating legally in another state, now sits at the center of a court fight that could criminalize its arrival.

That fight is not happening in isolation. Planned Parenthood of Wisconsin has filed its own lawsuit in Dane County challenging a mandatory 24-hour waiting period and physician-only provision rules that restrict medication abortion via telehealth. And at the federal level, the American Civil Liberties Union reports that a federal appeals court has taken up another challenge to mifepristone — the same drug at the center of Louisiana's case.

For patients tracking their options, three questions are worth raising with a trusted provider before deciding anything: how your state currently regulates telemedicine prescribing, whether the medication you are considering is classified as a controlled substance where you live, and whether your provider can lawfully mail it to your zip code. The legal terrain is moving quickly, and the answers differ sharply state by state.